Related Experiment Video

Updated: Aug 11, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.7K

Drug Development in Soft Tissue Sarcomas: Novel Targets and Recent Early Phase Trial Results

Ella Achenbach1, David Lai1, Shiraj Sen1

  • 1Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.

Journal of Immunotherapy and Precision Oncology
|February 8, 2023
PubMed

Insights

Novel drug development for soft tissue sarcomas is advancing due to a better understanding of tumor biology. This review covers new targets, early clinical trial results, and potential FDA approvals for these rare cancers.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Soft tissue sarcomas are rare, heterogeneous mesenchymal tumors with limited effective treatments.
  • Advances in understanding sarcoma biology are driving new therapeutic strategies.

Purpose of the Study:

  • To review novel molecular targets in soft tissue sarcoma.
  • To summarize early clinical trial data for drugs targeting these novel pathways.
  • To discuss the clinical utility and future approval prospects of these investigational agents.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of data from early-phase clinical trials.
  • Evaluation of current clinical practice and regulatory pathways.

Main Results:

  • Several novel targets are emerging in soft tissue sarcoma research.
  • Early clinical trials show promising, albeit preliminary, results for targeted therapies.
  • Data supports the potential for future US Food and Drug Administration (FDA) approvals.

Conclusions:

  • Targeted drug development holds promise for improving outcomes in soft tissue sarcomas.
  • Continued research and clinical trials are crucial for advancing treatment options.
  • Understanding tumor biology is key to identifying effective therapies for these rare malignancies.
Keywords:
clinical trialsdrug developmentsarcoma

More Related Videos

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.4K
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
616